IOB - Delayed Quote • SEK Elekta AB (publ) (0O5H.IL) Follow Compare 63.35 +0.07 +(0.12%) At close: January 17 at 4:29:56 PM GMT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Discover AlphaCorp And 2 Other Stocks That May Be Priced Below Their Estimated Value As global markets navigate a mixed economic landscape, with U.S. consumer confidence and manufacturing indicators showing signs of softness amidst moderate gains in major stock indexes, investors are increasingly focused on identifying opportunities that may be undervalued. In this context, finding stocks priced below their estimated value can offer potential advantages, especially when market conditions reflect both volatility and growth prospects. 3 Stocks That May Be Priced Below Their Estimated Worth In November 2024 As global markets show signs of resilience, with U.S. indexes approaching record highs and broad-based gains reported, investors are navigating a landscape marked by geopolitical tensions and economic policy shifts. Amid this environment, identifying stocks that may be priced below their estimated worth can offer potential opportunities for those looking to capitalize on market inefficiencies. Understanding the value of a stock in relation to its current price is crucial, especially when... Elekta AB (EKTAF) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Innovations Elekta AB (EKTAF) reports mixed results with a focus on new product launches and cost-saving initiatives amid declining sales and margins. Are Investors Undervaluing Elekta (EKTAY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Are Investors Undervaluing Avanos Medical (AVNS) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Is Elekta (EKTAY) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Should Value Investors Buy Avanos Medical (AVNS) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Is Elekta (EKTAY) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Should Value Investors Buy Elekta (EKTAY) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Elekta's Q1 beats estimates, shares jump At 5:30 am (0930 GMT), Elekta was trading 5.7% higher at SEK 72.95. The company's quarterly results exceeded expectations in terms of both sales and profitability, providing a much-needed boost to its stock, which had experienced significant declines in recent months. Elekta's First quarter results were marked by a 10% increase in order intake at constant currency (CER), well above the consensus expectation of no growth. Elekta shares slump after weaker-than-anticipated fourth-quarter earnings Investing.com -- Stockholm-listed shares in Elekta (ST:EKTAb) dropped to bottom of the pan-European Stoxx 600 on Wednesday after the Swedish radiation therapy group reported a fall in fourth-quarter profit that was larger than anticipated. Elekta introduces AI-powered adaptive CT-Linac The CT-Linac is designed to deliver both offline and online adaptive radiation therapy. GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions. GE Healthcare subsidiary expands radiation therapy partnership with Elekta MIM Software, which GE Healthcare acquired earlier this month, will work with Elekta to improve treatment planning and workflows. Performance Overview Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return 0O5H.IL OMX Stockholm 30 Index YTD +4.58% +5.41% 1-Year -17.77% +12.64% 3-Year -31.82% +10.99%